Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Selection of primary breast cancer patients for adjuvant endocrine therapy- is oestrogen receptor alone adequate?
Autore:
Cheung, KL; Nicholson, RI; Blamey, RW; Robertson, JFR;
Indirizzi:
City Hosp, Professorial Unit Surg, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB t Surg, Nottingham NG5 1PB, England Tenovus Inst Canc Res Ctr, Cardiff, S Glam, Wales Tenovus Inst Canc Res Ctr Cardiff S Glam Wales r, Cardiff, S Glam, Wales
Titolo Testata:
BREAST CANCER RESEARCH AND TREATMENT
fascicolo: 2, volume: 65, anno: 2001,
pagine: 155 - 162
SICI:
0167-6806(200101)65:2<155:SOPBCP>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESTROGEN-RECEPTOR; PROGNOSTIC INDEX; PROGESTERONE RECEPTORS; MEGESTROL-ACETATE; EARLY RECURRENCE; CYCLIN D1; SURVIVAL; OVEREXPRESSION; C-ERBB2; RELAPSE;
Keywords:
ER; breast cancer; adjuvant endocrine therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Cheung, KL City Hosp, Professorial Unit Surg, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB tingham NG5 1PB, England
Citazione:
K.L. Cheung et al., "Selection of primary breast cancer patients for adjuvant endocrine therapy- is oestrogen receptor alone adequate?", BREAST CANC, 65(2), 2001, pp. 155-162

Abstract

Among 834 patients who had primary breast cancer treated by surgery without adjuvant systemic therapy, 363 had relapse treated by endocrine therapy alone. Patients with oestrogen receptor positive tumours (median: 70 vs. 45 months, p < 0.0001) or with non-progression at 6 months of therapy (median:111 vs. 37 months, p < 0.0001) survived longer than those with oestrogen receptor negative tumours or with disease progression respectively, presumably due to the effect of therapy. On the other hand, the median disease-freeinterval, uninfluenced by therapy, showed a similar difference: oestrogen receptor positive versus negative = 29 versus 21 months, p < 0.005; non-progression versus progression = 40 versus 19 months, p < 0.0001. Patients with oestrogen receptor-positive tumours and non-progression at 6 months had the longest disease-free interval. The present study has established that there are factors, other than the oestrogen receptor, inherent in the primarytumour as reflected by the disease-free interval, which affect hormone sensitivity. Selection of adjuvant endocrine therapy based on the oestrogen receptor alone would deem inadequate. Further studies to elucidate other possible factors are warranted to refine the use of endocrine therapy, especially in the adjuvant setting when no indication of response is available.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 00:29:43